News & Articles

Early Clinical Findings Demonstrate Concert Pharmaceuticals’ CTP-656’s Potential as Once Daily Poten

Concert applies its proprietary deuterium chemistry approach to known drug compounds that it believes can be improved with deuterium substitution to enhance clinical safety, tolerability or efficacy. Its pipeline of product candidates includes CTP-656, a novel potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein for the treatment of cystic fibrosis. CTP-656 is being developed as a monotherapy or for use with other CFTR modulators. CTP-656 is a novel once daily dosed CFTR potentiator that was developed by applying deuterium chemistry to modify ivacaftor, known commercially as Kalydeco®. Deuterium is essentially identical to hydrogen in size and shape, with

Join us in Istanbul for the 2nd Saudi Paediatric Pulmonology Association SPPA Conference from 14th  

The 2nd Annual SPPA Conference Istanbul 2016 April 14-16, 2016 Dear Partner, On behalf of the Saudi Paediatric Pulmonology Association , and the Organizing Committees, We are pleased to announce the 2nd Saudi Paediatric Pulmonology Association SPPA Conference from 14th to 16th April, 2016 in Marriott Hotel Asia, Istanbul, Turkey. The conference will be held in collaboration with Saudi Thoracic Society, Arab Paedoiatric Pulmo- nology Association (APPA), The Turkish Thoracic Society, and Middle East Cystic Fibrosis Asso- ciation (MECFA). The conference will have two full days of scientific program and a pre- conference half day for workshops and associations meeting and discussions.

Featured Posts
Recent Posts
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean